100XBIO

100XBIO is a private, early-stage biotech tools company that has developed an integrated hardware and software platform for automated, gentle cell staining and analysis. Its core innovation, Hybrid Cytometry, allows researchers to perform serial treatments and fluorescence scans on the same cells, first in a live state and then after fixation, capturing dynamic functional data alongside detailed phenotypic data. The company is pre-revenue, targeting the cell therapy, immunology, and oncology research markets with a platform designed to automate complex bioassays. Its near-term strategy involves engaging with research teams in the Boston biotech hub to validate and adopt its technology.

Hybrid Cytometry Platform: An integrated hardware and software system for automated, gentle cell staining and analysis. It enables 'live-then-fixed' assays on the same cells, combining dynamic live-cell fluorescence imaging with subsequent in situ fixation and high-parameter staining in a single, loss-minimized workflow.

100XBIO competes indirectly with traditional flow cytometry providers (e.g., BD Biosciences, Beckman Coulter) and live-cell imaging/high-content analysis systems (e.g., Sartorius/Incucyt, PerkinElmer, Molecular Devices). Its unique value proposition is the integration of these two modalities into a single, automated, gentle workflow—a niche not fully addressed by current market leaders.